@article{3078534,
    title = "Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials",
    author = "Weisel, K. and Majer, I. and DeCosta, L. and Oriol, A. and Goldschmidt, H. and Ludwig, H. and Campioni, M. and Szabo, Z. and Dimopoulos, M.",
    journal = "Clinical Lymphoma Myeloma and Leukemia",
    year = "2020",
    volume = "61",
    number = "1",
    pages = "37-46",
    publisher = "Taylor and Francis Ltd.",
    doi = "10.1080/10428194.2019.1648806",
    keywords = "bortezomib;  carfilzomib;  daratumumab;  dexamethasone;  antineoplastic agent;  bortezomib;  carfilzomib;  dexamethasone;  oligopeptide, adult;  aged;  Article;  cancer combination chemotherapy;  cancer recurrence;  cancer survival;  clinical article;  comparative effectiveness;  comparative study;  constipation;  diarrhea;  drug efficacy;  drug safety;  embolism;  female;  heart failure;  human;  hypertension;  male;  multiple cycle treatment;  multiple myeloma;  nausea;  peripheral neuropathy;  phase 3 clinical trial (topic);  priority journal;  progression free survival;  risk reduction;  thrombosis;  vomiting;  drug resistance;  treatment outcome, Antineoplastic Combined Chemotherapy Protocols;  Bortezomib;  Dexamethasone;  Drug Resistance, Neoplasm;  Humans;  Multiple Myeloma;  Oligopeptides;  Treatment Outcome",
    abstract = "In ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents were administered until disease progression; the EU label for Vd, however, stipulates a maximum of eight treatment cycles. Here, matching-adjusted treatment comparison was used to compare efficacy of Kd56 with Vd, if Vd was administered for 8 cycles (Vd-8). Data from ENDEAVOR and CASTOR trials (which compared daratumumab, bortezomib, and dexamethasone with Vd-8) were used. Hazard ratios of PFS were estimated for Vd vs. Vd-8 and Kd vs. Vd-8. For cycles 1–8, risk reduction in PFS for Kd56 vs. Vd-8 was equal to that estimated in ENDEAVOR (HR: 0.53; 95% CI 0.44–0.65). Beyond eight cycles, risk reduction in PFS for Kd56 and Vd-8 was estimated to be 60% (HR: 0.40; 95% CI 0.26–0.63). The analysis suggested that PFS benefit of Kd56 over Vd increases when Vd is given for eight cycles only. © 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group."
}